Genetic factors in individual responses to environmental exposures

Journal of Occupational and Environmental Medicine

Volumn 37, Issue 1, 1995, Pages 37-43

  Hirvonen, Ari ^a,b  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; CANCER RISK; CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; LUNG CANCER; REVIEW;

ARYLAMINE N-ACETYLTRANSFERASE; BLADDER NEOPLASMS; CARCINOGENS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REGULATOR; GLUTATHIONE TRANSFERASE; HUMAN; LUNG NEOPLASMS; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES; POLYMORPHISM (GENETICS);

EID: 0028967509     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/00043764-199501000-00006     Document Type: Article

References (72)

1. Idle JR. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res. 1991;247:259-266.
2. Nebert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res. 1991;247:267-281.
3. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res Suppl. 1991; 51:5023s-5044s.
4. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and Glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in Japanese population. Cancer Res. 1993;53:2994-2999.
5. Ioannides C, Parke DW. The cytochromes P-448—a unique family of enzymes involved in chemical toxicity and carcinogenesis. Biochem Pharmacol. 1987;36:4197-4207.
6. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther. 1990;45:1-38.
7. Kellerman G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med. 1973;289:934-937.
8. Petruzzelli S, Camus AM, Carrozzi L, Chelarducci L, Rindi M, Menconi G, Angeletti CA, Ahotupa M, Hietanen E, Aitio A, Saracci R, Bartsch H, Giuntini C. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: A case-control study on lung cancer patients. Cancer Res. 1988;48:4695-4700.
9. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM. Castegnaro M, Alexandrov K, Rojas M, Saracci R, Giuntini C. Carcinogen metabolism in human lung tissues and effect of tobacco smoking: results from a case-control multi-center study on lung cancer patients. Environ Health Perspect. 1992; 98:119-124.
10. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1990;48:720-725.
11. Wedlund P, Kimura S, Gonzalez F, Nebert D. 142V mutation in the human CYP1A1 gene: lack of correlation with either the MspI 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of East Mediterranean descent. Pharmacogenetics. 1994;4:21-26.
12. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility of squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 1991;51:5177-5189.
13. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated Msp I polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem. 1991; 110:407-411.
14. 1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of of lung cancer in a Norwegian population. Pharmacogenetics. 1991;1:20-25.
15. Shields PG, Sugimura H, Caporaso NE, Petruzzelli SF, Bowman ED, Trump BF, Weston A, Harris CC. Polycyclic aromatic hydrocarbons-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect. 1992;98:191-194.
16. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and T to C mutation in the 3′-flanking region. Clin Invest. 1994;72:240-248.
17. Sugimura H, Suzuki I, Hamada GS, Iwase T, Takahashi T, Nagura K, Iwata H, Watanabe S, Kino I, Tsugane S. Cytochrome P-450 IA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prev. 1994;3:145-148.
18. Hirvonen A, Husgafvel-Pursiainen H, Kaijalainen A, Anttila S, Vainio H. Point-mutational Msp I and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev. 1992; 1:485-489.
19. Burbach KM, Poland A, Bradfield CA. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci. 1992;89:8185-8189.
20. Schmidt JV, Carver LA, Bradfield CA. Structural organization of the Ah locus. J Biol Chem. 1993;268:22203-22209.
21. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (ARNT) as a component of the DNA binding form of the Ah receptor. Science. 1992; 256:1193-1195.
22. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis. 1994;15:801-806.
23. Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, Sugimura H, Weston A, Harris CC. The debrisoquine metabolic phenotype and DNA-based assays: implications of mis-classification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect. 1992;98:101-105.
24. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988; 331:442-446.
25. Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Carcinogenesis. 1990; 11:1527-1530.
26. Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-1 restriction fragment length polymorphism. Br J Clin Pharmacol. 1991;32:283-288.
27. Heim M, Meyer UA. Genotyping poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-532.
28. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 1990;347:773-776.
29. Roots I, Brockmoller J, Drakoulis N, Loddenkemper R. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest. 1992;70:307-319.
30. Agúndez JAG, Martinez C, Ladero J, Ledesma MC, Ramos JM, Martin R, Rodriguez, Jara C, Benitez J. Debriso-quin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther. 1994;55:10-14.
31. sWolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 1992;13:1035-1038.
32. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brøgger A, Børresen A.-L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics. 1994;4:47-57.
33. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, Crespi CL. Characterization of a human cell line expressing high levels of cDNA-de-rived CYP2D6. Pharmacogenetics. 1993;3:28-39.
34. Hirvonen A, Husgafvel-Pursiainen H, Anttila S, Kaijalainen A, Pelkonen O, Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics. 1993;3:19-27.
35. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics. 1994;4:104-106.
36. London SJ, Daly AK, Thomas DC, Caporaso NE, Idle JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk. Pharmacogenetics. 1994; 4:107-108.
37. Johansson I, Lundqvist E, Bertilsson L, Dahl M.-L., Sjӧqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
38. Rushmore TH, Pickett CB. Glutathione 5-transferases, structure, regulation, and therapeutic implications. J Biol Chem. 1993;268:11475-11478.
39. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The glutathione 5-trans-ferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect. 1992;98:87-94.
40. Seidegård J, Pero RW, Miller DG, Beat-tie EJ. A glutathione transferase in human leukocytes as a marker for susceptibility to lung cancer. Carcinogenesis. 1986;7:751-753.
41. Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class g) as a marker for susceptibility to lung cancer: a follow-up study. Carcinogenesis. 1990;11:33-36.
42. Strange RC, Matharoo B, Faulder GC, Jones P, Cotton W, Elder JB, Deakin M. The human glutathione S-transferases: a case-control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis. 1991; 12:25-28.
43. Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG. Glutathione 5-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst. 1992;84:414-422.
44. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA. 1988;85:7293-7297.
45. Bell DA, Thompson CL, Taylor J, Miller CR, Perera F, Hsich LL, Lucier GW. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase g. Environ Health Perspect. 1992;98:113-117.
46. Zhong S, Wyllie H, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTMI genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis. 1993; 14:1821-1824.
47. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione 5-transferase µ locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis. 1991;12:1533-1537.
48. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Homung SK, Leng Z-T, Stapleton P, Weiss N. The glutathione S-transferase µ (GSTM1) as a marker for susceptibility to lung carcinoma. Cancer Res. 1993;53:2313-2318.
49. Brockmӧller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class µ isoenzymes g and in lung cancer patients and controls. Cancer Res. 1993; 53:1004-1011.
50. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis. 1993; 14:1479-1481.
51. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 1994; 15:415-418.
52. Lafuente A, Pujol F, Carreterro P, Villa JP, Cuchi A. Human glutathione 5-transferase µ (GST/µ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett. 1993;68:49-54.
53. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of gene for glutathione 5-transferase Ml in bladder cancer. BMJ. 1993;307:481-482.
54. Bell D, Taylor JA, Paulson D, Robertson, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen metabolism gene glutathione transferase g (GSTM1) increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85:1159-1164.
55. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis. 1994;15:813-815.
56. Evans DAP. N-acetyltransferase. Pharmacol Ther. 1989;42:157-234.
57. Nebert DW, Weber WW. Pharmacogenetics. In: Pratt WB, Taylor P, eds. Principles of Drug Action. The Basis of Pharmacology. Churchill Livingstone. New York; 1990:469-531.
58. Weber WW, Mattano SS, Levy GN. Acetylation pharmacogenetics and aromatic amine-induced cancer. In: King CM, ed. Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes. Elsevier, New York; 1988; 115-123.
59. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992;98:69-74.
60. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta. 1988;948:37-66.
61. Sinues B, Perez J, Bernal ML, Saenz MA, Lanuza J, Bartolome M. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res. 1992;52:4885-4889.
62. Vineis P, Caporaso N, Tannenbaum SR, Skipper PL, Glogowski J, Bartsch H, Coda M, Talaska G, Kadlubar FF. Acetylation phenotype, carcinogen-hemoglobin adducts and cigarette smoking. Cancer Res. 1990;50:3002-3004.
63. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields P, Skipper P, Talaska G, Tannenbaum SR. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994;369:154-156.
64. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylator phenotype in colorectal carcinoma. Cancer Res. 1987;47:1466-1469.
65. Wohleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZJ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer. 1990;46:22-30.
66. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez MJ, Baki W, Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res. 1991;51:2098-2100.
67. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193-203.
68. Oshako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyl-transferases from human liver. J Biol Chem. 1990;265:4630-4634.
69. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci. 1991;88:5237-5241.
70. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 1993;301:71-76.
71. Fredrickson SM, Messing EM, Reznikoff CA, Swaminathan S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uro-epithelial cells. Cancer Epidemiol Biomarkers Prev. 1994;3:25-32.
72. Hayesh RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL, Meyer UA. N-acetylationphenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis. 1993; 14:675-678.